-
Nat Med: What is the effect of β-thalassemia adult globin lentiviral gene therapy?
Time of Update: 2022-01-07
stem cellIt can be seen that these relevant results emphasize the need to closely monitor β-thalassemia patients receiving treatment with globin carriers .
These related results emphasize the need to closely monitor β-thalassemia patients receiving treatment with globin carriers .
-
What should I do when the TT result becomes an asterisk and the retest is invalid?
Time of Update: 2022-01-07
But liver function and other blood coagulation results are normal, and there are anticoagulants similar to lupus in the body?However, after asking the clinician, there was no clear result, so he consulted with the engineer.
-
Ann Oncol: The updated data of the ECHELON-2 study shows that A+CHP continues to improve the prognosis of patients with CD30+ peripheral T-cell lymphoma (PTCL) compared with CHOP
Time of Update: 2022-01-07
The researchers conducted a phase III clinical study of ECHELON-2 (NCT01777152) to evaluate the CD30 antibody brentuximab vedotin (bentuximab) combined with CHP (A+CHP) versus CHOP for the treatment of CD30-positive (CD30+) peripheral T-cell lymphoma (PTCL) Efficacy and safety of patients .
-
2021 ASH Professor Guangsheng He: New discovery of Chinese real-world evidence and efficacy prediction of Eltrombopag combined with IST in the treatment of SAA
Time of Update: 2022-01-01
Yimaitong: Another study published by your team on the efficacy predictors of Eltrombopag combined with IST in the treatment of SAA patients in China was also included in this year’s ASH poster.
-
"Sleeping Beauty" CAR-T Therapy in the Treatment of Acute Myeloid Leukemia Phase 1 Clinical Results Actively Revealed the News
Time of Update: 2022-01-01
·Altaltaltalt December 17, 2021/MedClub News/--Recently, at the 63rd American Society of Hematology (ASH) Annual Meeting in 2021, Precigen announced cells based on its non-viral vector UltraCAR-T™ platform Therapy PRGN-3006 has positive clinical data from the Phase 1/1b clinical trial for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) .
-
[Blood] The first study to block two cytokines at the same time provides new ideas for the treatment of inflammatory diseases!
Time of Update: 2022-01-01
Author: Liz Zee Guide: A new study led by researchers at the University of California, Davis, shows that blocking IL-6 and TNF cytokines is a way to prevent life-threatening transplants Graft-versus-host-disease (GVHD) provides a more effective method.
-
2021 ASH Professor Yang Renchi: The results of the phase Ib study are announced. HMPL-523 is expected to open a new pattern of ITP treatment
Time of Update: 2022-01-01
The results of a phase Ib clinical study (NCT03951623) evaluating the safety and preliminary efficacy of HMPL-523 in adult patients with primary immune thrombocytopenia (ITP) will be reproduced in the form of an oral report during the ASH annual meeting in 2021.
-
Progress in new drugs Deqi Pharma's first new drug was approved for listing in China!
Time of Update: 2022-01-01
S. Food and Drug Administration (FDA) approved selinexor (XPOVIO®) combined with low-dose dexamethasone for the treatment of patients with refractory relapsed multiple myeloma (rrMM) .
In addition, Karyopharm announced that the ongoing phase 3 SIENDO trial of selinexor (XPOVIO®) for the treatment of endometrial cancer patients has completed the planned interim invalidity analysis.
-
ASH Express 2021│Professor Li Caixia: The effectiveness and safety of targeting CD19/CD22 CAR-T combined with tislelizumab in the treatment of relapsed and refractory B-NHL
Time of Update: 2022-01-01
Research method: A prospective single-arm study was conducted on CAR-T cells combined with anti-PD-1 antibody in the treatment of R/R B-NHL patients (NCT04539444) .
Research conclusions: These results show that CAR-T cells combined with anti-PD-1 antibodies can produce a safe and long-lasting response in R/R B-NHL patients.
-
Wonderful review｜Break the "array" PNH regional series of forums
Time of Update: 2022-01-01
At 7 pm on December 15th, 2021, the PNH regional series of “Breaking the Array” was successfully held online. This meeting specially invited Professor Wang Shunqing from Guangzhou First People’s Hos
-
Nat Med: How effective is Tisagenlecleucel in treating relapsed or refractory follicular lymphoma?
Time of Update: 2021-12-27
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor T cell therapy that has shown clinically significant results in patients with relapsed/refractory B-cell lymphoma .
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
-
Haemophilia: Real-world experience of the tolerability and safety of emicizumab prevention in children with severe hemophilia A with and without FVIII inhibitors
Time of Update: 2021-12-27
An existing study aimed to demonstrate the real-world experience of the tolerability, side effects and results of emicizumab in the prevention of adverse events in pediatric PwHA was collected at Birmingham Children’s Hospital Hemophilia Comprehensive Care Center from March 2018 to June 2021.
-
U.S. FDA expands indications for sickle cell disease drug Oxbryta
Time of Update: 2021-12-27
Global Blood Therapeutics (GBT) recently stated that the FDA has expanded the indications of Oxbryta (voxelotor) to allow it to treat sickle cell disease (SCD) in children under 4 to 12 years of age .
-
AJH: Cerebral venous thrombosis and myeloproliferative tumors: a three-center study of 74 consecutive cases
Time of Update: 2021-12-27
The recent association between cerebral venous thrombosis (CVT) and COVID-19 vaccination also prompted researchers to investigate 74 cases of CVT associated with myeloproliferative tumors (MPN) (median age = 44 years, range 15-85; 61%) Women) conduct a retrospective review .
-
Leukemia: The dual targeting of JAK2 and ERK interferes with myeloproliferative tumor cloning and improves the therapeutic effect
Time of Update: 2021-12-26
Competitive transplantation of Jak2 V617F with wild-type bone marrow (BM) showed that ERK1/2 deficiencies in hematopoiesis alleviated MPN characteristics and reduced V617F clones in the blood and hematopoietic progenitor cell compartments of Jak2 .
-
NEJM: Milvexian is used to prevent venous thromboembolism
Time of Update: 2021-12-26
In patients undergoing knee arthroplasty, oral milvexian inhibition of factor XIa after surgery can effectively prevent venous thromboembolism and is associated with a low risk of bleeding .
-
A case of red blood cell condensation leading to deviation of routine blood count
Time of Update: 2021-12-26
5pg, MCHC 321g/L, at this time the red blood cell aggregation abnormal alarm message disappears, indicating that the red blood cell aggregation is reversible, and the aggregation phenomenon disappears after the temperature is restored .
-
What should I do if the red blood cell agglutination cannot be corrected by the warm bath?
Time of Update: 2021-12-26
So the specimens were tested after being heated at 37°C for 30 minutes, and the results were as follows:It can be seen from the results that although MCH and MCHC have decreased, the red blood cell histogram is still abnormal, and red blood cell agglutination has not been corrected .
-
Platelets fluctuated high and low, how did you send such a report?
Time of Update: 2021-12-26
What caused it?So the author checked the blood routine history records and hospitalization records of the patient since he was admitted to the hospital, and after careful comparison and thinking, he found that the platelets increased every time the patient had a fever, and the sputum culture showed fungal spores .
-
NEJM: Daprodustat for treatment of anemia in chronic kidney disease without dialysis
Time of Update: 2021-12-26
The primary endpoint of the study was the average change in the patient’s hemoglobin level from baseline examination to weeks 28-52, and the first major adverse cardiovascular event (MACE; death from any cause, non-fatal myocardial infarction, or non-fatal stroke) .
